Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus DOXY 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus DOXY 200.
ACHROMYCIN vs DOXY 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
200 mg orally once daily or 100 mg orally every 12 hours.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic